Sunepitron | 131831-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Sunepitron
• 英文别名: 1-[[(7S,9aS)-2-pyrimidin-2-yl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-yl]methyl]pyrrolidine-2,5-dione
• CAS: 131831-03-3
• 化学式: C₁₇H₂₃N₅O₂
• 分子量: 329.4
• InChiKey: UXWBIYCPUVWKHP-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS
  申请人：PFIZER INC.

  公开号：WO1990008144A1

  公开（公告）日：1990-07-26

  (EN) Anxiolytic agents which are racemic or optically active pyrido[1,2-a]pyrazine derivatives of formula (I), wherein X is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals; and intermediates therefor.(FR) On décrit des agents anxiolytiques qui sont racémiques ou des dérivés optiquement actifs de pyrido(1,2-a)pyrazine ayant la formule (I) selon laquelle X constitue N ou CH et Y représente un radical parmi certains radicaux de pyrazole, de triazole, de tétrazole ou d'imide cyclique; et des intermédiaires de ceux-ci.

  一种具有式(I)的手性或外消旋的吡啶[1,2-a]吡嗪衍生物的抗焦虑剂，其中X为N或CH，Y代表某些嘧啶唑，三唑，四唑或环状亚酰胺基团之一；以及其中间体。
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.
• 5 HT RECEPTOR MEDIATED NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20100009983A1

  公开（公告）日：2010-01-14

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
• US5122525A
  申请人：——

  公开号：US5122525A

  公开（公告）日：1992-06-16